Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have been given a consensus recommendation of “Buy” by the twenty-five ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and seventeen have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $65.52.
Several equities research analysts recently issued reports on SRPT shares. Goldman Sachs Group reiterated a “buy” rating and issued a $71.00 price target on shares of Sarepta Therapeutics in a research note on Friday, October 6th. ValuEngine cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Janney Montgomery Scott initiated coverage on Sarepta Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $75.00 target price for the company. Oppenheimer restated a “buy” rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. Finally, BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, December 25th.
In other news, CEO Douglas S. Ingram purchased 38,138 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were acquired at an average price of $52.44 per share, with a total value of $1,999,956.72. Following the completion of the transaction, the chief executive officer now owns 420,196 shares of the company’s stock, valued at approximately $22,035,078.24. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total transaction of $372,618.63. Following the sale, the director now directly owns 13,333 shares in the company, valued at approximately $745,181.37. The disclosure for this sale can be found here. Corporate insiders own 9.60% of the company’s stock.
Shares of Sarepta Therapeutics (NASDAQ SRPT) traded down $0.15 during mid-day trading on Monday, hitting $58.99. The company had a trading volume of 1,632,325 shares, compared to its average volume of 2,409,646. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $3,810.00, a PE ratio of -28.92 and a beta of 1.37. Sarepta Therapeutics has a fifty-two week low of $26.26 and a fifty-two week high of $60.22.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.66. The business had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the previous year, the company posted ($0.95) earnings per share. equities research analysts predict that Sarepta Therapeutics will post -3.07 earnings per share for the current fiscal year.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.